CN120018855A - 治疗脊髓小脑性共济失调的方法 - Google Patents

治疗脊髓小脑性共济失调的方法 Download PDF

Info

Publication number
CN120018855A
CN120018855A CN202380041989.8A CN202380041989A CN120018855A CN 120018855 A CN120018855 A CN 120018855A CN 202380041989 A CN202380041989 A CN 202380041989A CN 120018855 A CN120018855 A CN 120018855A
Authority
CN
China
Prior art keywords
dosage form
patient
administered
weeks
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380041989.8A
Other languages
English (en)
Chinese (zh)
Inventor
V·科里奇
M·贝纳
I·库雷什
G·利塔连
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiaohaifen Therapeutics Co ltd
Original Assignee
Baiaohaifen Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baiaohaifen Therapeutics Co ltd filed Critical Baiaohaifen Therapeutics Co ltd
Publication of CN120018855A publication Critical patent/CN120018855A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380041989.8A 2022-05-23 2023-05-23 治疗脊髓小脑性共济失调的方法 Pending CN120018855A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263344917P 2022-05-23 2022-05-23
US63/344,917 2022-05-23
PCT/US2023/067326 WO2023230451A2 (en) 2022-05-23 2023-05-23 Methods of treating spinocerebellar ataxias

Publications (1)

Publication Number Publication Date
CN120018855A true CN120018855A (zh) 2025-05-16

Family

ID=88920175

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380041989.8A Pending CN120018855A (zh) 2022-05-23 2023-05-23 治疗脊髓小脑性共济失调的方法

Country Status (6)

Country Link
US (1) US20260124183A1 (cg-RX-API-DMAC7.html)
EP (1) EP4529485A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025517509A (cg-RX-API-DMAC7.html)
KR (1) KR20250020409A (cg-RX-API-DMAC7.html)
CN (1) CN120018855A (cg-RX-API-DMAC7.html)
WO (1) WO2023230451A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók
WO2026062600A1 (en) * 2024-09-22 2026-03-26 Biohaven Therapeutics Ltd. Troriluzole for use in treating spinocerebellar ataxias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018154462A2 (en) * 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
PT3706739T (pt) * 2017-11-12 2024-12-04 Biohaven Therapeutics Ltd Utilização de profármacos de riluzol para tratar ataxias
US20210308111A1 (en) * 2018-07-27 2021-10-07 With Great Power, Llc Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers
US20230067811A1 (en) * 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease

Also Published As

Publication number Publication date
EP4529485A2 (en) 2025-04-02
WO2023230451A3 (en) 2024-01-04
JP2025517509A (ja) 2025-06-05
WO2023230451A2 (en) 2023-11-30
EP4529485A4 (en) 2026-05-20
KR20250020409A (ko) 2025-02-11
US20260124183A1 (en) 2026-05-07

Similar Documents

Publication Publication Date Title
US20190160078A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US10201528B2 (en) Method of treating multiple sclerosis
JP7365426B2 (ja) 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法
US10537566B2 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
TW202128183A (zh) 用於治療多種病症之方法及組成物
US10946026B2 (en) Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US10285981B2 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
EP3706739B1 (en) Use of riluzole prodrugs to treat ataxias
US20100063116A1 (en) Use of pramipexole or a salt thereof for the treatment of parkinson's disease
US20260124183A1 (en) Methods of treating spinocerebellar ataxias
KR20120050512A (ko) 탈수초를 갖는 환자에서 4-아미노피리딘을 사용한 지속적 치료
CN110831590A (zh) 含有培马贝特的医药
CN121079083A (zh) 高强度单单位剂量制剂和其使用方法
US20220370468A1 (en) Methods of treating sleep disorders associated with pain
WO2026062600A1 (en) Troriluzole for use in treating spinocerebellar ataxias
WO2025228863A1 (en) Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative
US20190134006A1 (en) Method of treating multiple sclerosis
HK40033906A (en) Use of riluzole prodrugs to treat ataxias
HK40033906B (en) Use of riluzole prodrugs to treat ataxias
EA049071B1 (ru) Применение пролекарств рилузола для лечения атаксии
HK1160586A (en) Durable treatment with 4-aminopyridine in patients with demyelination

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination